Cargando…
The lung microbiome in end-stage Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a progressive cystic lung disease with mortality driven primarily by respiratory failure. Patients with LAM frequently have respiratory infections, suggestive of a dysregulated microbiome. Here we demonstrate that end-stage LAM patients have a distinct microbiome si...
Autores principales: | Ng, Julie, Pacheco-Rodriguez, Gustavo, Begley, Lesa, Huang, Yvonne J., Poli, Sergio, Perrella, Mark A., Rosas, Ivan O., Moss, Joel, El-Chemaly, Souheil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549264/ https://www.ncbi.nlm.nih.gov/pubmed/34702264 http://dx.doi.org/10.1186/s12931-021-01873-y |
Ejemplares similares
-
Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer
por: El-Chemaly, Souheil, et al.
Publicado: (2014) -
Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis
por: Lamattina, Anthony M., et al.
Publicado: (2019) -
Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion
por: Esposito, Anthony J, et al.
Publicado: (2023) -
The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis
por: Courtwright, Andrew M., et al.
Publicado: (2017) -
Unexpected sirolimus-stimulated airway hyperreactivity in lymphangioleiomyomatosis
por: Steagall, Wendy K., et al.
Publicado: (2023)